[{"orgOrder":0,"company":"USV Private Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Linagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"USV Private Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"USV Private Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"USV Private Limited \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Linagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.029999999999999999,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Lupin Ltd"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkem Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alkem Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Linagliptin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Empanorm L (empagliflozin-linagliptin) is an SGLT-2/DPP-4 inhibitor indicated for use in the treatment of type-2 diabetes mellitus, CKD and chronic heart failure (HF).

                          Product Name : Empanorm L

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 13, 2025

                          Lead Product(s) : Empagliflozin,Linagliptin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Glempa-L (empagliflozin-linagliptin) is an SGLT-2/DPP-4 inhibitor indicated for use in the treatment of type-2 diabetes mellitus, CKD and chronic heart failure (HF).

                          Product Name : Glempa-L

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 13, 2025

                          Lead Product(s) : Empagliflozin,Linagliptin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Trijardy XR-Generic is a combination product of empagliflozin, linagliptin & metformin hydrochloride which is indicated for the treatment of adults with type 2 diabetes mellitus.

                          Product Name : Trijardy XR-Generic

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 10, 2024

                          Lead Product(s) : Empagliflozin,Linagliptin,Metformin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Liralin (linagliptin) is a DPP-4 (Dipeptidyl peptidase IV) inhibitor, oral small molecule drug which is approved for the treatment of type-2-diabetes mellitus.

                          Product Name : Liralin

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 04, 2023

                          Lead Product(s) : Linagliptin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Through the acquisition, Lupin expands its diabetes portfolio in India by gaining access to Ondero (linagliptin) and Ondero Met (linagliptin & metformin). Ondero is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes...

                          Product Name : Ondero

                          Product Type : Miscellaneous

                          Upfront Cash : $28.3 million

                          August 18, 2023

                          Lead Product(s) : Linagliptin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Lupin Ltd

                          Deal Size : $28.3 million

                          Deal Type : Acquisition

                          blank

                          06

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Linagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 13, 2016

                          Lead Product(s) : Linagliptin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Eli Lilly

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Genuine Research Center, Egypt

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Genuine Research Center, Egypt

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Details : Linagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 05, 2016

                          Lead Product(s) : Linagliptin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Eva Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Northwell Health

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Northwell Health

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Details : Linagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 11, 2016

                          Lead Product(s) : Linagliptin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          University of Washington

                          Country arrow
                          PackExpo
                          Not Confirmed

                          University of Washington

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Lead Product(s) : Linagliptin

                          Therapeutic Area : Nephrology

                          Study Phase : Undisclosed

                          Sponsor : American Diabetes Association | Medtronic plc | Abbott Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Linagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Renal Insufficiency, Chronic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 18, 2015

                          Lead Product(s) : Linagliptin

                          Therapeutic Area : Nephrology

                          Highest Development Status : Undisclosed

                          Sponsor : American Diabetes Association | Medtronic plc | Abbott Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          George Washington University

                          Country arrow
                          PackExpo
                          Not Confirmed

                          George Washington University

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Details : Linagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 10, 2015

                          Lead Product(s) : Linagliptin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Boehringer Ingelheim GmbH

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank